The sickle cell disease implementation consortium: Translating evidence‐based guidelines into practice for sickle cell disease
Year: 2018
Type: article
Abstract: the centrifugation-based washing did not translate into the corresponding changes in key metrics of RBC in vitro quality, including deformability (see Supporting Information).This finding suggests that the probability of each individual RBCs to be damaged by centrifugation is likely independent of the cell's properties, and therefore hemolysis of damaged cells during the 24-h storage does not affect the overall quality of the sample.In contrast, our earlier work has shown that selective lysis of RBCs irreversibly damaged during hypothermic storage (sphero-echinocytes and spherocytes) via hypotonic washing produced ORCID
Source: American Journal of Hematology
DOI: 10.1002/ajh.25282
Institutions: RTI International, Washington University in St. Louis, University of Illinois Chicago, Medical University of South Carolina, Icahn School of Medicine at Mount Sinai, University of California, San Francisco, UCSF Benioff Children's Hospital, Georgia Southern University, University of Memphis, University of California Davis Medical Center, University of California, Davis, Duke University, Duke Medical Center, Augusta University, Augusta University Health, St. Jude Children's Research Hospital
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Australian Government, bluebird bio, National Institutes of Health, Centers for Disease Control and Prevention, U.S. Food and Drug Administration, University of Illinois at Chicago, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Research Resources, National Center for Advancing Translational Sciences, National Institute on Minority Health and Health Disparities, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: G1125781002, G127766916, G1320814302, Virginia Commonwealth University Sickle Cell Disease Clinical Network, G1548123974, G1588992266, Clinical and Translational Science Institute, G1849108715, G1865158448, PEDIATRIC CLINICAL RESEARCH CENTER, G2095060056, G2204229864, G2405024849, G2536572524, G2544189534, G2724382595, G2908589470, G3320014004, Transfusion Medicine/Hemostasis Clinical Trials Network, Harvard Clinical and Translational Science Center (UL1), G3557002732, G3591806655, G3682557505, G3789537736, G3813675775, G3848050108, Thalassemia Clinical Research Network, G4497844540, G464080255, Thalassemia Clinical Research Network, in vivo Studies of Clinical Stage Globin Modulators, G4772206542, G4775533232, Implementation of a Sickle Cell Enhanced Novel Care Network in South Carolina (iSCENSC), G4827657020, G483408255, G4878390933, G5016758722, G5265491106, General Clinical Research Center, G5531805118, G5533752783, G5583629992, G5645816113, G5745184621, Child Health Career Development Program at UCSF, G5977062928, New York City Sickle Cell Implementation Science Consortium, G6151519511, G6362927184, G638673952, Modulation of Iron Deposition in SCD and Other Hemoglobinopathies, Zinc and Bone Metabolism in Thalassemia, G6582556994, G6691326575, Next Generation Therapeutics for Hemoglobinopathies, PREVENTION OF COMPLICATIONS IN THALASSEMIA, G687132063, G693953337, G7002159072, G7221635693, Thalassemia Clinical Research Network, Canada, G7333336489, G742032275, Institutional Clinical and Translational Science Award, G772888159, G7823699828, Basic and Translational Research Program (BTRP) in Sickle Cell Disease, NEW INVESTIGATION INITIATIVES FOR THE PREVENTION OF COMPLICATIONS OF THALASSEMIA, G7888730243, G8094512817, G838680220, G876475942, G8863054946, G8999607219, Clinical and Translational Science Center, G901581866, G960100943
OpenAlex ID: W2889700593